Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus
Eur J Med Chem. 2024 Mar 18;269:116343. doi: 10.1016/j.ejmech.2024.116343. Online ahead of print.ABSTRACTSodium-dependent glucose transporters 2 (SGLT2) inhibitors are a class of small-molecule drugs that have gained significant attention in recent years for their potential clinical applications in the treatment of type 2 diabetes mellitus (T2DM). These inhibitors function by obstructing the kidneys' ability to reabsorb glucose, resulting in a rise in the excretion of glucose in urine (UGE) and subsequently lowering blood glucose levels. Several SGLT2 inhibitors, such as Dapagliflozin, Canagliflozin, and Empagliflozin, hav...
Source: European Journal of Medicinal Chemistry - March 21, 2024 Category: Chemistry Authors: Tong Xie Li-Jie Zhao Source Type: research
Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction
CONCLUSIONS: Empagliflozin is effective in reducing LV volumes and hospitalisation rate in patients with type 2 diabetes and prediabetes and HFrEF. Therefore, treatment with empagliflozin for six months was associated with a significant reduction in adverse cardiovascular outcomes in these patients.PMID:38511517 | DOI:10.1080/00015385.2023.2240130 (Source: Atherosclerosis)
Source: Atherosclerosis - March 21, 2024 Category: Cardiology Authors: Mohammad Reza Afshani Ekhlas Torfi Nehzat Akiash Alireza Jahanshahi Asghar Mohamadi Omid Sherafat Source Type: research
Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin
Biochem Pharmacol. 2024 Mar 20;223:116140. doi: 10.1016/j.bcp.2024.116140. Online ahead of print.ABSTRACTCancer cells consume more glucose and usually overexpress glucose transporters which have become potential targets for the development of anticancer drugs. It has been demonstrated that selective SGLT2 inhibitors, such as canagliflozin and dapagliflozin, display anticancer activity. Here we demonstrated that canagliflozin and dapagliflozin synergistically enhanced the growth inhibitory effect of paclitaxel in cancer cells including ovarian cancer and oral squamous cell carcinoma cells. Canagliflozin also inhibited gluco...
Source: Biochemical Pharmacology - March 21, 2024 Category: Drugs & Pharmacology Authors: Haoning Huang Fan-Lu Kung Yu-Wen Huang Chun-Chien Hsu Jih-Hwa Guh Lih-Ching Hsu Source Type: research
Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction
CONCLUSIONS: Empagliflozin is effective in reducing LV volumes and hospitalisation rate in patients with type 2 diabetes and prediabetes and HFrEF. Therefore, treatment with empagliflozin for six months was associated with a significant reduction in adverse cardiovascular outcomes in these patients.PMID:38511517 | DOI:10.1080/00015385.2023.2240130 (Source: Acta Cardiologica)
Source: Acta Cardiologica - March 21, 2024 Category: Cardiology Authors: Mohammad Reza Afshani Ekhlas Torfi Nehzat Akiash Alireza Jahanshahi Asghar Mohamadi Omid Sherafat Source Type: research
Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus
Eur J Med Chem. 2024 Mar 18;269:116343. doi: 10.1016/j.ejmech.2024.116343. Online ahead of print.ABSTRACTSodium-dependent glucose transporters 2 (SGLT2) inhibitors are a class of small-molecule drugs that have gained significant attention in recent years for their potential clinical applications in the treatment of type 2 diabetes mellitus (T2DM). These inhibitors function by obstructing the kidneys' ability to reabsorb glucose, resulting in a rise in the excretion of glucose in urine (UGE) and subsequently lowering blood glucose levels. Several SGLT2 inhibitors, such as Dapagliflozin, Canagliflozin, and Empagliflozin, hav...
Source: European Journal of Medicinal Chemistry - March 21, 2024 Category: Chemistry Authors: Tong Xie Li-Jie Zhao Source Type: research
Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction
CONCLUSIONS: Empagliflozin is effective in reducing LV volumes and hospitalisation rate in patients with type 2 diabetes and prediabetes and HFrEF. Therefore, treatment with empagliflozin for six months was associated with a significant reduction in adverse cardiovascular outcomes in these patients.PMID:38511517 | DOI:10.1080/00015385.2023.2240130 (Source: Acta Cardiologica)
Source: Acta Cardiologica - March 21, 2024 Category: Cardiology Authors: Mohammad Reza Afshani Ekhlas Torfi Nehzat Akiash Alireza Jahanshahi Asghar Mohamadi Omid Sherafat Source Type: research
SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study
Sodium-glucose cotransporter 2 (SGLT2) inhibition is recognized for its evident renoprotective benefits in diabetic renal disease. Recent data suggest that SGLT2 inhibition also slows down kidney disease progr... (Source: Lipids in Health and Disease)
Source: Lipids in Health and Disease - March 20, 2024 Category: Lipidology Authors: Zhijuan Wang, Jie Wei, Wenman Zhao, Rui Shi, Yuyu Zhu, Xunliang Li and Deguang Wang Tags: Research Source Type: research
Cancer cells hijack physiological metabolic signals to seed liver metastasis
Cancer Res. 2024 Mar 19. doi: 10.1158/0008-5472.CAN-24-0835. Online ahead of print.ABSTRACTMetastasis arises from cancer-cell intrinsic adaptations and permissive tumor microenvironments (TME) that are distinct across different organs. Deciphering the mechanisms underpinning organotropism could provide novel preventive and therapeutic strategies for cancer patients. Rogava and colleagues identified Pip4kc as a driver of liver metastasis, acting by sensitizing cancer cells to insulin-dependent PI3K/AKT signaling, which could be reversed by dual pharmacological inhibition of PI3K and SGLT2 or a ketogenic diet. The study high...
Source: Cell Research - March 19, 2024 Category: Cytology Authors: Andres Rettig Karuna Ganesh Source Type: research
2023 Diabetic Kidney Disease Fact Sheet in Korea
CONCLUSION: DKD is prevalent among Korean patients with diabetes and is an independent risk factor for cardiovascular morbidity and mortality, which requiring intensive management of diabetes and comorbidities. The prevalence of diabetes-related ESKD has been increasing, especially in the older adults, during past decade.PMID:38499437 | DOI:10.4093/dmj.2023.0310 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - March 18, 2024 Category: Endocrinology Authors: Nam Hoon Kim Mi-Hae Seo Jin Hyung Jung Kyung Do Han Mi Kyung Kim Nan Hee Kim Diabetic Kidney Disease Research Group of the Korean Diabetes Association Source Type: research
Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?
J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. doi: 10.1590/2175-8239-JBN-2023-0146en.ABSTRACTThe prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis. The aim of this review is to analyze the current data and potential effects of iSGLT2 in lithogenesis and try to answer the question: Should we also "gliflozin" our patients with kidney stone disease?PMID:38498673 | DOI:10.1590/2175-8239-JBN-2023-0146en (Source: Jornal Brasileiro de Nefrologia)
Source: Jornal Brasileiro de Nefrologia - March 18, 2024 Category: Urology & Nephrology Authors: Mauricio de Carvalho Ita Pfeferman Heilberg Source Type: research
Functional and metabolomic analysis of urinary extracellular vesicles from juvenile mice with renal compensatory hypertrophy
This study suggests that uEVs contain bioactive components capable of inducing protective, anti-inflammatory, anti-fibrinolytic, and antioxidative effects in renal cells. These findings contribute to our understanding of uEVs' role in renal compensatory mechanisms after unilateral nephrectomy and may hold promise for future therapeutic interventions in renal diseases.PMID:38499276 | DOI:10.1016/j.bbadis.2024.167096 (Source: Biochimica et Biophysica Acta)
Source: Biochimica et Biophysica Acta - March 18, 2024 Category: Biochemistry Authors: Rasha Aly Sara Darwish Niharika Bala Areej Ebrahim Lawrence R Shoemaker Joel McCray Timothy J Garrett Abdel A Alli Source Type: research
2023 Diabetic Kidney Disease Fact Sheet in Korea
CONCLUSION: DKD is prevalent among Korean patients with diabetes and is an independent risk factor for cardiovascular morbidity and mortality, which requiring intensive management of diabetes and comorbidities. The prevalence of diabetes-related ESKD has been increasing, especially in the older adults, during past decade.PMID:38499437 | DOI:10.4093/dmj.2023.0310 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - March 18, 2024 Category: Endocrinology Authors: Nam Hoon Kim Mi-Hae Seo Jin Hyung Jung Kyung Do Han Mi Kyung Kim Nan Hee Kim Diabetic Kidney Disease Research Group of the Korean Diabetes Association Source Type: research
Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?
J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. doi: 10.1590/2175-8239-JBN-2023-0146en.ABSTRACTThe prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis. The aim of this review is to analyze the current data and potential effects of iSGLT2 in lithogenesis and try to answer the question: Should we also "gliflozin" our patients with kidney stone disease?PMID:38498673 | DOI:10.1590/2175-8239-JBN-2023-0146en (Source: Jornal Brasileiro de Nefrologia)
Source: Jornal Brasileiro de Nefrologia - March 18, 2024 Category: Urology & Nephrology Authors: Mauricio de Carvalho Ita Pfeferman Heilberg Source Type: research
